Biosimilars cut cancer immunotherapy costs in India
The story in brief
Biosimilar drugs are making immunotherapy more affordable for cancer patients in India, with nivolumab's biosimilar showing effectiveness in 25 tumours. Doctors report a 50% rise in prescriptions as patients now afford the treatment at Rs 30,000 per cycle. A TMC study found only 2.8% of eligible patients received immunotherapy in 2022, but prescriptions have surged. Survival rates for melanoma patients have jumped from 5% to 50% with immunotherapy.